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THE dextran sodium sulphate (DSS) induced colitis in
mice was used as a experimental model to study the
contractility of murine longitudinal colonic smooth
muscle  during  inflammation.  Smooth  muscle  seg-
ments  of  proximal,  middle  and  distal  colon  were
mounted in organ baths. Smooth muscle contraction
was  induced  by  carbachol,  showing  an  aboral
increase in activity, whereas in the inflamed middle
colonic segment  a  marked  decrease  in activity  was
observed.  The  dilatative  effect  of  sodium-nitroprus-
side (SNP)  as a nitric oxide donor was investigated
after  precontraction  by  carbachol.  Both  in  normal
and DSS segments administration of SNP to isolated
mouse  colonic  smooth  muscle  preparations  caused
regional differences in relaxation, the highest relaxa-
tion seen  in  normal  proximal colonic  tissue.  How-
ever,  this  relaxation  was  markedly  reduced  in
inflamed  proximal  preparations,  associated  with  a
diminished cGMP contents.
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Introduction
The dextran sodium sulphate (DSS) induced colitis in
mice
1 is at present a well documented experimental
model to study formation of inflammatory mediators
and the use of therapeutics in ulcerative colitis (UC).
This mild colitis is mainly characterized by infiltration
of  neutrophils,  diarrhoea,  rectal  blood  and  loss  of
body weight.
2 Besides the disease dependent release
of lipid mediators and cytokines,
3 enhanced colonic
nitric  oxide  (NO)  generation  could  influence  the
disease  activity  in  UC  and  Crohn’s  disease.  Several
investigators have demonstrated increased concentra-
tions  of  NO  in  intestinal  mucosa  of  patients  with
inflammatory bowel disease (IBD).
4–6 Increased con-
centrations of NO could not only result in damage of
epithelial cells and apoptosis, but also lead to mucosal
vasodilatation,  an  increased  vasopermeability  and  a
decreased  colonic  motility. Therefore  high  mucosal
levelds  of  endogenous  NO  may  mediate  gut  motor
disfunction and other clinical features as abdominal
pain, malabsorption and granulomatous inflammation
in IBD.
7,8 As a result of downregulatory mechanisms,
smooth muscle response to NO is inhibited by high
endogenous NO production. Moreover reduction of
NO  synthase  activity  could  lead  to  a  reduced
relaxation.
In this study we investigated the effect of NO from
exogenous sodium nitroprusside (SNP) on both nor-




The study protocol had been approved by the local
Animal Ethical Committee (no. 118–97–01). Colonic
smooth  muscle  preparations  were  obtained  from
BALB/c mice (female, 20–22 g, IFFA Credo, France).
Colitis  was  induced  by  adding  10%  (w/v)  dextran
sodium sulphate (MW > 500 000, Pharmacia, Sweden)
to their drinking water, ad libitum for 8 days. Controls
received tap water. After overnight fastin mice were
killed by cervical dislocation. Immediately thereafter
the colon was removed. Total length (approx 90 mm)




Upon  sacrifice,  the  removed  bowel  was  examined
macroscopically.  Signs  of  inflammation  (diarrhoea,
blood)  and  changes  in  tissue  appearance  (oedema,
thickening) were scored (0–2).  Pieces of  proximal,
middle  and  distal  colon  were  taken  for histological
analysis. The sections were fixated in 3.6% buffered
formalin,  pH  7,  and  embedded  in  paraffin  wax.
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haematotoxylin and azafloxin were examined under a
light  microscope  using  a  4003 magnification. The
histology score obtained from each section (blinded
scored including inflammation 0–3, damage/necrosis
0–3 and regeneration 0–3) ranged from 0 to 9 was
combined  with  the  macroscopic  score  (0–3)  and
used as the disease activity score (DAS; 0–12).
10
Organ bath
Whole longitudinal  colonic smooth muscle prepara-
tions (including mucosa, circular layer and neuronal
plexus) were mounted in 10 ml double-jacketed organ
baths containing Krebs solution heated to 37°C and
continuously  gassed  with  5%  CO2 in  O2. The  con-
tractile  responses  were  measured  isotonically  using
Penny & Giles transducers (pre-load 500 mg). Cumu-
lative contraction-response curves were prepared by
adding agonists in small volumes. Preparations were
pre-contracted with 300 mM KCl, the optimum con-
centration found in blood vessel organ bath observa-
tions.
11 After washing (three times bath fluid contents
every  5 min), contraction  was induced by  the mus-
carinic receptor agonist carbachol (Sigma Chemicals)
in doses of 10
–8 to 10
–3 M, reaching stable maximal
smooth  muscle  contraction.  Contraction  was
expressed  as mg  displacement.  Without  washing
relaxation  by  SNP  (Sigma  Chemicals)  in  doses  of
8.4.10
–8 to 8.4.10
–4 M was induced. Relaxation was
expressed  as  percentage  fall  in  contraction. After  a
second  washing regime  carbachol  induced  contrac-
tion  (10
–3 M)  was  antagonized  by  the  b 2-receptor
agonist salbutamol in doses of 10
–8 to 10
–3 M. Bath
samples were taken for measurements of NO2/NO3
(NOx )  and  cyclic  GMP  (Biotrak-assay,  Amersham,
UK).
3 Maximum  (ECmax)  and  half-maximum  (EC50)
contractions  and  relaxations  were  calculated  after
computer  programmed  plotting  of  dose–response
curve  fitting.  Results  are  expressed  as  mean  ±
standard error. Statistical analysis included Wilcoxon’s
test for unpaired samples (in case of DAS activities)
and Student’s t-test (other observations).
Results
Inflammation
After  macroscopic  and  microscopic  evaluation  we
observed a  mild to moderate disease activity  in the
DSS-induced colitis mice (DAS in proximal colon: 6.4
± 1.57 and in middle colon: 6.3 ± 1.10). Distal colonic
preparations tended to show a dimished DAS (4.4 ±
0.79),  mainly  due  to  the  absence  of  thickening,
oedema,  faecal  blood  and  diarrhoea.  Histologically
inflammation was limited to mucosa and submucosa
(neutrophil infiltrations), without involving muscular
layers.
Contractility
In normal tissues we observed an increased contrac-
tion after carbachol in aboral direction (Fig. 1: distal >
middle  >  proximal  colon).  In  inflammation  this
carbachol-induced contraction was markedly reduced
in  middle  colonic  segments.  In  the  non-inflamed
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FIG. 1. Effect of carbachol induced contraction in mouse longitudinal colonic smooth muscle preparations in controls (left
panel) and dextran sodium sulphate (DSS)-induced colitis (right panel). Contraction is expressed asmg displacement of the
isotonic transducer. n=8.SNP-induced relaxation in colitis
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FIG.  2.  Effect  of  sodium  nitroprusside  (SNP)  relaxation  in  mouse  longitudinal  colonic  smooth  muscle  preparations
precontracted with carbachol 10–3 M (100%) in controls (left panel) and dextran sodium sulphate (DSS)-induced colitis (right
panel), expressed as percentage relaxation. n=8.
FIG. 3. Effect of salbutamol induced relaxation in mouse longitudinal colonic smooth muscle preparations precontracted with
carbachol 10–3 M (100%) in controls (left panel) and dextran sodium sulphate (DSS)-induced colitis (right panel), expressed as
percentage relaxation. n=8.
proximal colon SNP showed a much higher relaxation
(mean  Emax 48%)  than  those  observed  in  middle
(mean Emax 27%) and distal (mean Emax 12%) colonic
preparations, precontracted by carbachol. Nitroprus-
side-induced  relaxation  however  was  significantly
reduced (‡  70%) in  DSS-induced inflamed proximal
preparations  (mean  Emax 15%)  and  of  the  same
magnitude as the middle (mean Emax 22%) and distal
(mean  Emax 9%)  preparations  which  tended  to
decrease (Fig. 2). A similar pattern was observed after
induction of salbutamol-evoked relaxations between
controls and DSS preparations (Fig. 3), although the
difference in relaxations between the proximal  seg-
ments was less prominent.NOx
The net total  NO release after addition  of SNP was
determined as NO2/NO3. No regional nor control-DSS
differences were found (Table 1).
Cyclic GMP
In the bath fluids cGMP content was measured after
SNP-evoked relaxation (Table 2). Levels measured in
baths  from  DSS  preparations  were  lower,  although
this  was  only  significant  in  proximal  preparations
(P<0.05, Student’s t-test).
Discussion
Normal  longitudinal  colon  smooth  muscle  contrac-
tion induced by carbachol showed an aboral increase.
A  marked  decrease  in  activity  was  observed  in  the
middle segment of the inflamed colon. However, no
correlation was found between severity of inflamma-
tion and disturbed contractility, as carbachol-induced
effects  in  the  more  inflamed  colon  were  less  pro-
nounced. We found an increased SNP-induced relaxa-
tion in normal proximal tissue, which was observed
in  the  most  inflamed,  proximal  colonic  smooth
muscle preparations. Normal and inflamed proximal
segments converted SNP into NO, measured as NOx
Cyclic  GMP  contents  however  were  significantly
decreased in the inflamed proximal colon bath fluid.
This  reduction  in  cGMP  was  correlated  with  the
diminished SNP-induced relaxation.
In  normal,  non-inflamed  rat  colonic  segments,
Maehara et al.
12 found no differences between NO-
evoked  release  of  cGMP  in  proximal  and  distal
preparations, although relaxation  in  proximal  colon
was more prominant than in distal colon. This effect
was attributed however to the release of vasoactive
intestinal  peptide  (VIP),  a  mediator  with  dilative
properties, which only was detected in distal colon.
Our  study  is  the  first  in  which  contractility  was
investigated  in  inflamed  colonic  preparations  from
DSS-mice. Very recently it was shown that in longitu-
dinal  strips  from  trinitrobenzenesulphonic  acid
(TNBS)-treated ileum in guinea pigs there was a two-
fold increase in maximal response induced by carba-
chol and histamine without modification of the EC50
values.
13 This  observation  is  in  contrast  with  our
present  findings. This  could  be  due  to  a  different
model of inflammation, as TNBS is a direct toxin to
mucosal epithelium and DSS-induced inflammation is
very likely triggered by changes in intestinal macro-
phage  function  and  bacterial  flora.
14 In  our  model
smooth muscles were not visibly altered. The marked
neutrophil  infiltration  could  contribute  to  an
enhanced production of NO, which in turn will lead
to  a  diminished  smooth  muscle  contraction.  Fur-
thermore  Martinolle  et  al.
13 used  the  ileum  from
guinea pigs, and literature on NO production in both
species  and  ileum is not  available yet.  Nitric  oxide
synthetase activity however was five-fold increased in
mucosa  taken  from  patients  with  ulcerative  colitis,
but unchanged in those from Crohn’s disease.
15 This
indicates that cell-specific generation of inflammatory
mediators or local susceptibility  of smooth muscles
will determine the  outcome of NO production  and
contractility.
In controls the salbutamol induced relaxation was
similar in all preparations. This indicates the presence
of  a  normal  second  messenger  system,  which  only
was  affected  in  inflamed  proximal  segments. After
SNP application a significant decrease in cGMP levels
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Table 1. NOx release in organ baths (m M) after carbachol (10–3 M) and nitroprusside (8.4 10–4 M) application (n=4)
Controls
Resting Carbachol Carbachol + NP
DSS-colitis
Resting Carbachol Carbachol + NP
Proximal 174 ± 9 184 ± 10 860 ± 39 171 ± 15 166 ± 13 802 ± 65
Middle 168 ± 12 135 ± 33 838 ± 89 170 ± 17 155 ± 7 712 ± 46
Distal 171 ± 7 152 ± 17 770 ± 65 170 ± 10 159 ± 5 665 ± 55
Table 2. cGMP organ bath levels (nM) after carbachol (10–3 M) and nitroprusside (8.4 10–4 M) application (n=4)
Controls
Resting Carbachol Carbachol + NP
DSS-colitis
Resting Carbachol Carbachol + NP
Proximal 24 ± 12 157 ± 49 609 ± 219 4 ± 4 100 ± 33 138 ± 33*
Middle 8 ± 7 48 ± 3 98 ± 43 3 ± 3 32 ± 7 42 ± 14
Distal 19 ± 11 99 ± 17 188 ± 55 9 ± 6 68 ± 18 93 ± 25
*P < 0.05 DSS vs. controls.was found. During chronic inflammation of the colon
the ongoing production of NO could diminish guany-
late  cyclase  activity  resulting  in  a  decreased
relaxation.
It  is  also  possible  that  carbachol-evoked  cGMP
release  will  influence  the  threshold  necessary  to
obtain  relaxation  after  pre-contraction  with  carba-
chol. Recently it was shown that the nerve stimula-
tion-induced muscarinic NO release in the guinea pig
likely is mediated by M1 muscarinic receptor activa-
tion.
16 Comparable  with  observations  in  lung  dis-
eases, negative feedback by M2 muscarinic receptor
activation  could  be  depleted  in  inflamed  colonic
tissue.
17 In  colitis  this  mechanism  of  action  needs
further investigation.
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